The use of immunotherapies in the treatment of metastatic cancers has significantly advanced oncology. However, due to safety concerns, solid organ transplant recipients (SOTRs) are routinely excluded from immunotherapy trials; thus, there is limited data for these agents in this population.
A systematic review was performed to evaluate the safety and efficacy of immunotherapies in SOTRs with metastatic cancers. Fisher's exact test and Kruskal-Wallis test were used for analysis.
In total, 37% of patients experienced organ rejection, and 14% died as a result of graft rejection. Nivolumab was associated with the highest rejection rate (52.2%), followed by pembrolizumab (26.7%) and ipilimumab (25%; P = .1774). The highest rejection rate was seen in patients with kidney transplants (40.1%), then liver (35%) and heart (20%) transplants (P = .775), and 64% of patients succumbed to the progression of malignancy. For all cases, rates of progression or death secondary to disease were highest for ipilimumab (75%), followed by nivolumab (43%) and pembrolizumab (40%; P = .1892). The overall response rate was highest for pembrolizumab (40%), followed by nivolumab (30%) and ipilimumab (25%; P = .7929).
The small sample size.
Physicians must be cautious when administering immunotherapy to SOTRs. However, rejection is not the most common cause for death in this population.Le texte complet de cet article est disponible en PDF.
Key words : allograft rejection, CTLA-4 inhibitors, immune checkpoint inhibitors, PD-1 inhibitors, solid organ transplant
Abbreviations used : cSCC, CTLA-4, MCC, MM, PD-1, PD-L1, SOTR
| Funding sources: None.
| Conflicts of interest: Dr Zeitouni is a speaker for Genentech, Sanofi, and Biofrontera and has received research grants from Biofrontera and SunPharma. She is also on the advisory board for Sanofi and a consultant for InMed Pharmaceuticals. Dr Fisher, Ms Fan, and Dr Samie have no conflicts of interest to disclose.
| Reprints not available from the authors.